BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nuvalent\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Nuvalent\, Inc.'s drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05384626-10952@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:neladalkib: Phase 1/2 readout est. (NCT05384626)
DESCRIPTION:neladalkib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other So
 lid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-
 1)\nEstimated primary completion: December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/neladalkib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05384626
URL:https://assetmemo.bio/drug/neladalkib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05118789-2824@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zidesamtinib: Phase 1/2 readout est. (NCT05118789)
DESCRIPTION:Zidesamtinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Othe
 r Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/zidesamtinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05118789
URL:https://assetmemo.bio/drug/zidesamtinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06765109-10952@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:neladalkib: Phase 3 readout est. (NCT06765109)
DESCRIPTION:neladalkib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Nela
 dalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC\n
 Estimated primary completion: December 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/neladalkib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06765109
URL:https://assetmemo.bio/drug/neladalkib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
